Edwards Lifesciences (EW) Stock Falls on Q4 2025 Earnings

Edwards Lifesciences Corporation (EW) reported fourth-quarter 2025 results showing top-line growth alongside significant pressure on profitability.

Revenue: $1.57 billion (+13.3% year-over-year; estimate $1.59 billion)

Gross profit: $1.23 billion (+12.2% YoY)

Operating profit: $151.1 million (-51.7% YoY)

Net income attributable to common shareholders: $91.2 million (-76.4% YoY)

Diluted earnings per share: $0.16 (consensus estimate $0.6363)

Balance sheet and cash-flow highlights:

Cash from operating activities: $573.7 million (-549.96% YoY)

Purchases of property, plant and equipment: $57.5 million (+15.5% YoY)

Cash and cash equivalents: $2.69 billion (-11.8% YoY)

Total liabilities: $3.07 billion (+2.5% YoY)

Cost of sales: $343.0 million (+17.4% YoY)

Market reaction: the stock moved by 2.67% since market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Edwards Lifesciences Corporation Insider Trading Activity

Edwards Lifesciences Corporation insiders have traded $EW stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.

Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:

DONALD E JR BOBO (CVP,Strategy/Corp Development) has made 0 purchases and 5 sales selling 34,066 shares for an estimated $2,875,758.
BERNARD J ZOVIGHIAN (CEO) has made 0 purchases and 2 sales selling 25,350 shares for an estimated $2,153,373.
SCOTT B. ULLEM (CVP, Chief Financial Officer) has made 0 purchases and 3 sales selling 20,700 shares for an estimated $1,730,505.
LARRY L WOOD (Global President TAVR & Surg) sold 8,950 shares for an estimated $698,679
DAVEEN CHOPRA (CVP, TMTT & Surgical) has made 0 purchases and 2 sales selling 4,500 shares for an estimated $373,615.
DANIEL J. LIPPIS (CVP, TAVR) has made 0 purchases and 3 sales selling 3,058 shares for an estimated $257,153.
HEISZ LESLIE STONE sold 2,615 shares for an estimated $218,119
WAYNE MARKOWITZ (CVP, JAPAC) sold 583 shares for an estimated $50,143

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Edwards Lifesciences Corporation Hedge Fund Activity

We have seen 540 institutional investors add shares of Edwards Lifesciences Corporation stock to their portfolio, and 621 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 12,050,876 shares (+476.7%) to their portfolio in Q3 2025, for an estimated $937,196,626
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 9,692,916 shares (+656.5%) to their portfolio in Q3 2025, for an estimated $753,818,077
CITADEL ADVISORS LLC removed 8,496,721 shares (-66.7%) from their portfolio in Q3 2025, for an estimated $660,789,992
MILLENNIUM MANAGEMENT LLC removed 4,902,303 shares (-73.4%) from their portfolio in Q3 2025, for an estimated $381,252,104
MARSHALL WACE, LLP removed 3,329,080 shares (-48.3%) from their portfolio in Q3 2025, for an estimated $258,902,551
VIKING GLOBAL INVESTORS LP added 3,069,151 shares (+inf%) to their portfolio in Q3 2025, for an estimated $238,687,873
POINT72 ASSET MANAGEMENT, L.P. removed 2,307,323 shares (-75.9%) from their portfolio in Q3 2025, for an estimated $179,440,509

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Edwards Lifesciences Corporation Government Contracts

We have seen $28,429,350 of award payments to $EW over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

EXPRESS REPORT: HEART VALVES: $295,500
EXPRESS REPORT: 2ND QTR FY25 TAVR HEART VALVES WITH CONSIGNMENT DELIVERY: $261,500
HTM EV1000 PATIENT MONITORS: $246,000
HEART VALVE: $238,000
TRANSCATHETER HEART VALVE REPLACEMENT SYSTEMS: $238,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Edwards Lifesciences Corporation Congressional Stock Trading

Members of Congress have traded $EW stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $EW stock by members of Congress over the last 6 months:

REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 11/19.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Edwards Lifesciences Corporation Analyst Ratings

Wall Street analysts have issued reports on $EW in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Stifel issued a "Buy" rating on 01/20/2026
Piper Sandler issued a "Overweight" rating on 01/20/2026
Barclays issued a "Overweight" rating on 01/12/2026
TD Cowen issued a "Buy" rating on 01/09/2026
BTIG issued a "Buy" rating on 11/25/2025
Mizuho issued a "Outperform" rating on 10/31/2025
Goldman Sachs issued a "Buy" rating on 10/31/2025

To track analyst ratings and price targets for Edwards Lifesciences Corporation, check out Quiver Quantitative's $EW forecast page.

Edwards Lifesciences Corporation Price Targets

Multiple analysts have issued price targets for $EW recently. We have seen 17 analysts offer price targets for $EW in the last 6 months, with a median target of $98.0.

Here are some recent targets:

Rick Wise from Stifel set a target price of $110.0 on 01/20/2026
Adam Maeder from Piper Sandler set a target price of $98.0 on 01/20/2026
Matt Miksic from Barclays set a target price of $104.0 on 01/12/2026
Danielle Antalffy from UBS set a target price of $95.0 on 01/12/2026
Joshua Jennings from TD Cowen set a target price of $97.0 on 01/09/2026
Robbie Marcus from JP Morgan set a target price of $100.0 on 12/18/2025
William Plovanic from Canaccord Genuity set a target price of $87.0 on 12/17/2025